P&T for July

Click here to read the full issue in your browser Follow us

Dear VIJAY PITHADIA: Your July 2015 digital issue of P&T journal is available. This issue contains: Feature articles   Letter to the Editor   Clinical Trial Transparency Is Up for Grabs The FDA and Congress Are Expanding Public Access to Data Years of complaints about poor access to information on "compassionate use" of exper­i­mental drugs and a lack of transparency in clinical trials are driving reform efforts by the National Library of Medicine, the Food and Drug Administration, and Congress.   Vasopressor and Inotropic Management Of Patients With Septic Shock Many studies have evaluated the role of vasopressors and inotropes in the management of septic shock. This review assesses evidence for the use of specific vasopressors, adjunctive vasopressor therapy, and inotropic agents for myocardial dysfunction.   Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in The Management of Type-2 Diabetes: Drug Class Overview Sodium-glucose linked transporter 2 inhibitors limit the reabsorption of glucose from glomerular filtrate in the kidneys, reducing blood glucose levels in patients with type-2 diabetes. This article is meant to evaluate this class of medications for clinicians.   MEETING HIGHLIGHTS Digestive Disease Week We review key sessions on pharmacological treatment, including four on irritable bowel syndrome and others on pancreatitis and Helicobacter pylori infection.   PIPELINE PLUS Sepsis Treatment Options Are Often Lacking Life-threatening sepsis presents with varying symptoms due to the wide range of pathogens that cause it, and sepsis-specific treatment options for patients are sparse.   Plus our regular columns: Medication Errors, Prescription: Washington, New Drugs/Drug News/New Medical Devices, Pharmaceutical Approval Update, and Drug Forecast. Click here to begin reading the current issue. Click here to subscribe to P&T journal. Call for Papers P&T is accepting article submissions from its readers. We welcome a wide variety of manuscripts, including drug class reviews, disease state management reviews, pharmacoeconomic analyses, outcomes research evaluations, DUEs, P&T committee experiences, commentaries, book reviews, and letters to the editor. Please contact Sonja Sherritze, via phone (267-685-2779) or mobile 267-907-5642) or e-mail (ssherritze@medimedia.com) for more information. We hope you enjoy this issue of P&T. If you have any comments or questions about this digital format, please e-mail us at mail@ptcommunity.com. Sonja Sherritze Editor